Small sample clinical studies have shown that XPJYD can reduce serum LPS, D-lactic acid, DAO content in patients with depression and then reduce serum IL-6 and TNF-a content, indicating that XPJYD can repair the intestinal mucosal barrier and reduce the inflammatory response to a certain extent [26]. This evidence concerns the gene TNF and major depressive disorder.